BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30401981)

  • 1. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
    Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
    Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade.
    Tanaka I; Osada H; Fujii M; Fukatsu A; Hida T; Horio Y; Kondo Y; Sato A; Hasegawa Y; Tsujimura T; Sekido Y
    Oncogene; 2015 Jan; 34(1):73-83. PubMed ID: 24336325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
    Kim M; Kim T; Johnson RL; Lim DS
    Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.
    Cunningham R; Jia S; Purohit K; Salem O; Hui NS; Lin Y; Carragher NO; Hansen CG
    Clin Transl Med; 2023 Feb; 13(2):e1190. PubMed ID: 36740402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
    Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
    Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways.
    Santinon G; Pocaterra A; Dupont S
    Trends Cell Biol; 2016 Apr; 26(4):289-299. PubMed ID: 26750334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes.
    Mizuno T; Murakami H; Fujii M; Ishiguro F; Tanaka I; Kondo Y; Akatsuka S; Toyokuni S; Yokoi K; Osada H; Sekido Y
    Oncogene; 2012 Dec; 31(49):5117-22. PubMed ID: 22286761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.
    Sekido Y
    Pathol Int; 2011 Jun; 61(6):331-44. PubMed ID: 21615608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
    Maille E; Brosseau S; Hanoux V; Creveuil C; Danel C; Bergot E; Scherpereel A; Mazières J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Langlais A; Morin F; Levallet G; Zalcman G
    Br J Cancer; 2019 Feb; 120(4):387-397. PubMed ID: 30739911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
    Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
    BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
    Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
    J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations.
    Rehrauer H; Wu L; Blum W; Pecze L; Henzi T; Serre-Beinier V; Aquino C; Vrugt B; de Perrot M; Schwaller B; Felley-Bosco E
    Oncogene; 2018 May; 37(20):2645-2659. PubMed ID: 29507420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The polyomavirus middle T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner.
    Shanzer M; Ricardo-Lax I; Keshet R; Reuven N; Shaul Y
    Oncogene; 2015 Aug; 34(32):4190-8. PubMed ID: 25362852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
    Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
    J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors.
    Hagenbeek TJ; Webster JD; Kljavin NM; Chang MT; Pham T; Lee HJ; Klijn C; Cai AG; Totpal K; Ravishankar B; Yang N; Lee DH; Walsh KB; Hatzivassiliou G; de la Cruz CC; Gould SE; Wu X; Lee WP; Yang S; Zhang Z; Gu Q; Ji Q; Jackson EL; Lim DS; Dey A
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer.
    Vahid S; Thaper D; Gibson KF; Bishop JL; Zoubeidi A
    Sci Rep; 2016 Aug; 6():31842. PubMed ID: 27555231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.